Boston Scientific BSX Watchman — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Boston Scientific's watchman — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Boston Scientific's watchman — net sales?
- Boston Scientific (BSX) reported watchman — net sales of $506M in Q1 2026.
- How has Boston Scientific's watchman — net sales changed year-over-year?
- Boston Scientific's watchman — net sales increased by 19.1% year-over-year, from $425M to $506M.
- What is the long-term trend for Boston Scientific's watchman — net sales?
- Over 4 years (2021 to 2025), Boston Scientific's watchman — net sales has grown at a 24.0% compound annual growth rate (CAGR), from $829M to $1.96B.
- What does watchman — net sales mean?
- Total revenue generated from the sales of the company's left atrial appendage closure medical device product line.
- How do you interpret watchman — net sales?
- An increase indicates growing market adoption and successful clinical penetration of the device, while a decrease may signal increased competition or market saturation.
- How does watchman — net sales compare across companies?
- Comparable to revenue metrics for specific high-growth interventional cardiology or structural heart franchises at peer medical device manufacturers.